OBJECTIVE: This multi-center phase II trial was conducted by the Gynecologic Oncology Group to evaluate the activity and toxicity of irofulven in patients with previously treated adenocarcinoma of the endometrium. METHODS: Eligible patients had documented recurrent or persistent endometrial carcinoma after receiving definitive locoregional therapy, and were required to have measurable disease, performance status of 0-2, and adequate bone marrow, hepatic and renal functions prior to study entry. Patients were allowed one prior chemotherapy regimen. The initial dose of irofulven was 11 mg/m(2)/day for four days administered intravenously. Cycles were repeated every 28 days. Doses were escalated or reduced based on previous cycle toxicity. RESULTS: Twenty-five patients were enrolled onto the trial. There was one (4%) confirmed complete response. Seven (28%) patients had stable disease, with a median duration of 10.4 (range: 4.4-21.6) months. Patients received a median of one (range: 1-5) cycle of protocol treatment. There were three early treatment-related deaths due to renal failure and severe electrolyte disturbances. Two patients experienced grade 4 hematologic adverse effects. CONCLUSION: Irofulven administered at the dose and schedule used in this trial was minimally active and resulted in significant toxicity.
OBJECTIVE: This multi-center phase II trial was conducted by the Gynecologic Oncology Group to evaluate the activity and toxicity of irofulven in patients with previously treated adenocarcinoma of the endometrium. METHODS: Eligible patients had documented recurrent or persistent endometrial carcinoma after receiving definitive locoregional therapy, and were required to have measurable disease, performance status of 0-2, and adequate bone marrow, hepatic and renal functions prior to study entry. Patients were allowed one prior chemotherapy regimen. The initial dose of irofulven was 11 mg/m(2)/day for four days administered intravenously. Cycles were repeated every 28 days. Doses were escalated or reduced based on previous cycle toxicity. RESULTS: Twenty-five patients were enrolled onto the trial. There was one (4%) confirmed complete response. Seven (28%) patients had stable disease, with a median duration of 10.4 (range: 4.4-21.6) months. Patients received a median of one (range: 1-5) cycle of protocol treatment. There were three early treatment-related deaths due to renal failure and severe electrolyte disturbances. Two patients experienced grade 4 hematologic adverse effects. CONCLUSION:Irofulven administered at the dose and schedule used in this trial was minimally active and resulted in significant toxicity.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: J P Thomas; R Arzoomanian; D Alberti; C Feierabend; K Binger; K D Tutsch; T Steele; R Marnocha; C Smith; S Smith; J MacDonald; G Wilding; H Bailey Journal: Cancer Chemother Pharmacol Date: 2001-12 Impact factor: 3.333
Authors: S G Eckhardt; S D Baker; C D Britten; M Hidalgo; L Siu; L A Hammond; M A Villalona-Calero; S Felton; R Drengler; J G Kuhn; G M Clark; S L Smith; J R MacDonald; C Smith; J Moczygemba; S Weitman; D D Von Hoff; E K Rowinsky Journal: J Clin Oncol Date: 2000-12-15 Impact factor: 44.544
Authors: J R MacDonald; C C Muscoplat; D L Dexter; G L Mangold; S F Chen; M J Kelner; T C McMorris; D D Von Hoff Journal: Cancer Res Date: 1997-01-15 Impact factor: 12.701
Authors: Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun Journal: CA Cancer J Clin Date: 2003 Jan-Feb Impact factor: 508.702
Authors: Russell J Schilder; John A Blessing; Mark S Shahin; David S Miller; Krishnansu Sujata Tewari; Carolyn Y Muller; David P Warshal; Scott McMeekin; Jacob Rotmensch Journal: Int J Gynecol Cancer Date: 2010-10 Impact factor: 3.437
Authors: Kathleen N Moore; Michael W Sill; Meaghan E Tenney; Christopher J Darus; David Griffin; Theresa L Werner; Peter G Rose; Robert Behrens Journal: Gynecol Oncol Date: 2015-07-11 Impact factor: 5.482
Authors: Brian M Slomovitz; Yunyun Jiang; Melinda S Yates; Pamela T Soliman; Taren Johnston; Maureen Nowakowski; Charles Levenback; Qian Zhang; Kari Ring; Mark F Munsell; David M Gershenson; Karen H Lu; Robert L Coleman Journal: J Clin Oncol Date: 2015-01-26 Impact factor: 44.544
Authors: Carol Aghajanian; Michael W Sill; Kathleen M Darcy; Benjamin Greer; D Scott McMeekin; Peter G Rose; Jacob Rotmensch; Mack N Barnes; Parviz Hanjani; Kimberly K Leslie Journal: J Clin Oncol Date: 2011-05-02 Impact factor: 44.544
Authors: Michael J Kelner; Trevor C McMorris; Rafael J Rojas; Leita A Estes; Pharnuk Suthipinijtham Journal: Invest New Drugs Date: 2008-01-29 Impact factor: 3.850
Authors: Maria M Rubinstein; David M Hyman; Imogen Caird; Helen Won; Krysten Soldan; Kenneth Seier; Alexia Iasonos; William P Tew; Roisin E O'Cearbhaill; Rachel N Grisham; Martee L Hensley; Tiffany Troso-Sandoval; Paul Sabbatini; Joyce Guillen; S Duygu Selcuklu; Catherine Zimel; Jean Torrisi; Carol Aghajanian; Vicky Makker Journal: Cancer Date: 2019-12-27 Impact factor: 6.860